BioSpace News Archive

Deep Lens today announced the launch of its Real Time Feasibility offering, a new HIPAA-compliant tool designed to identify eligible patients and select the most effective sites in the Deep Lens Unity Network for oncology clinical trials in real-time.

Aurora Spine Corporation announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021.

Capsida Biotherapeutics Inc. today announced the appointment of Peter Anastasiou as the company’s Chief Executive Officer (CEO) and the promotions of Capsida co-founders Nicholas Flytzanis, Ph.D., to Chief Scientific Officer (CSO) and Nick Goeden, Ph.D., to Chief Technology Officer (CTO).

PureTech Health plc announced today the initiation of a clinical study of LYT-300 (oral allopregnanolone), PureTech’s wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others.

Harpoon Therapeutics, Inc. today announced that it will host a conference call and webcast to review the clinical status and provide an update on its pipeline programs.

L3Harris Technologies (NYSE:LHX) has completed the sale of its Narda-MITEQ business to an investment affiliate of J.F. Lehman & Company.